Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1SCLC 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1High Grade Serous Carcinoma 1Hereditary Sensory and Autonomic Neuropathies 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Malignancies 1Adenocarcinoma 1

Interventions

Everolimus 5Alpelisib 4berzosertib 3PX-866 3Letrozole 3Fulvestrant 3Cetuximab 3Topotecan 2NVP-BKM120 2tipifarnib 1sotorasib 1serabelisib 1ribociclib 1pembrolizumab 1parsaclisib 1palbociclib 1gedatolisib 1duvelisib 1ceralasertib 1capivasertib 1binimetinib 1Trimetazidine 1Paclitaxel 1Oxaliplatin 1Leuprolide 1Leucovorin 1Irinotecan 1Goserelin 1Fluorouracil 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hereditary Sensory and Autonomic Neuropathies × ceralasertib × Clear all
NCT04564027 2025-08-29

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

AstraZeneca

Phase 2 Completed
54 enrolled 16 charts

Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡